ArticleCell death discovery2026
Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The LIM domain and actin-binding protein 1 (LIMA1), as a cytoskeletal-associated tumor suppressor, has not yet been clearly characterized in bladder cancer (BLCA). This study found that the cytoskeletal protein LIMA1 plays a key tumor-suppressing role in BLCA. Clinical analysis revealed that LIMA1 is significantly downregulated in tumor tissues and serum, with its low expression positively correlated with clinical stage, pathological grade, and recurrence risk, and predictive of poor prognosis. Functionally, LIMA1 knockout promotes tumor cell proliferation, migration, and invasion, and increases tumor volume by 1.8-fold in a mouse subcutaneous xenograft model. Mechanistically, database prediction and molecular docking confirmed that LIMA1 directly binds to PINK1, enhancing mitochondrial autophagy by activating the PINK1-Parkin pathway. The mitochondrial autophagy inducer uric acid A reverses the malignant phenotype caused by LIMA1 deficiency. In summary, this study reveals the inhibitory role of the LIMA1/PINK1/mitochondrial autophagy pathway in BLCA progression, providing a theoretical basis for novel therapeutic strategies targeting this pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.